|Bid||440.60 x 800|
|Ask||441.98 x 1200|
|Day's Range||428.60 - 443.70|
|52 Week Range||65.49 - 497.49|
|Beta (5Y Monthly)||1.49|
|PE Ratio (TTM)||295.39|
|Earnings Date||Oct. 27, 2021 - Nov. 01, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||306.31|
Dr. Rishi Desai, Chief Medical Officer at Osmosis & Former Center for Disease Control and Prevention Epidemic Intelligence Officer discusses what will come next for booster shots.
What happened Shares of several COVID-19 vaccine makers were sliding on Monday. BioNTech stock (NASDAQ: BNTX) was down 6.5% at 12:09 p.m. EDT. Shares of Moderna (NASDAQ: MRNA) had slipped 4.4%. Novavax (NASDAQ: NVAX) stock had fallen 6%.
The European Union's (EU) drug regulator said on Monday it was evaluating whether a booster dose of Moderna's COVID-19 vaccine could be given at least six months after the second shot of the two-dose course in people over 12 years of age. The review by the European Medicines Agency (EMA) comes after its statement last week that it aims to decide in early October whether to endorse a booster for Pfizer-BioNTech vaccine, nearly a month after it started the evaluation process. "Although EMA and ECDC (European Centre for Disease Prevention and Control) do not consider the need for COVID-19 vaccine booster doses to be urgent in the general population, EMA is evaluating the present application to ensure evidence is available to support further doses as necessary," the EU regulator said.